Amgen announced that its cholesterol-lowering injectable drug Repatha significantly reduced risk of heart disease death, heart attack, and stroke in a 12,000-patient clinical trial focusing on primary prevention. The study expands the potential market for PCSK9 inhibitors by demonstrating benefit in patients without previous cardiovascular events. Despite initial commercial struggles, Repatha sales grew 22% in 2024 to $2.2 billion globally, with ongoing efforts to increase treatment urgency and uptake among patients not meeting LDL cholesterol goals.